MOUNTAIN VIEW, Calif., Jan. 12 /PRNewswire/ -- Aviron (Nasdaq: AVIR)
announced today that it has commenced public offerings of 3,000,000 shares of
its common stock and $150 million aggregate principal amount of convertible
subordinated notes.
The underwriters have the option to purchase up to an additional
450,000 shares (200,000 shares from selling stockholders and 250,000 shares
from the company) and an additional $22.5 million principal amount of notes to
cover over-allotments, if any. The managing underwriters for the offering will
be Morgan Stanley Dean Witter, JP Morgan, a division of Chase Securities Inc.,
and SG Cowen Securities Corporation.
A Registration Statement relating to the securities to be sold by the
selling stockholders has been filed with the Securities and Exchange
Commission but has not yet become effective. These securities may not be sold,
nor may offers to buy be accepted, prior to the time that Registration
Statement becomes effective.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any of these securities. There shall not be
any sale of these securities in any state in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the
securities laws of any such state.
Aviron is a biopharmaceutical company based in Mountain View, California,
focused on the prevention of disease through innovative vaccine technology.
Copies of the preliminary prospectuses relating to the public offerings
may be obtained by contacting Morgan Stanley Dean Witter, 1585 Broadway,
New York, NY, 10036, 212-761-4000; JP Morgan, 1 Bush Street, San Francisco,
CA, 94104, 415-439-3000; or SG Cowen Securities Corporation, 1 Financial
Square, 27th Floor, New York, NY, 10005, 212-495-7305.
SOURCE Aviron
 back to top
Related links:
http://www.aviron.com
Company News On-Call:
http://www.prnewswire.com/comp/114000.html or fax,
800-758-5804, ext. 114000
CONTACT:
Aviron, 650-919-6500
|
